Tumors with high tumor mutational burden (TMB) have also been correlated with objective response rate.34 Likewise, PD-L1 expression on tumor and immune cells has been demonstrated to be predictive of sensitivity to PD-1/PD-L1 blockade.35 The gene discussed is CD274; the disease is neoplasm.